TY - JOUR
T1 - Elucidation of the Strongest Predictors of Cardiovascular Events in Patients with Heart Failure
AU - Fukuda, Hiroki
AU - Shindo, Kazuhiro
AU - Sakamoto, Mari
AU - Ide, Tomomi
AU - Kinugawa, Shintaro
AU - Fukushima, Arata
AU - Tsutsui, Hiroyuki
AU - Ito, Shin
AU - Ishii, Akira
AU - Washio, Takashi
AU - Kitakaze, Masafumi
N1 - Funding Information:
Nothing to disclose for Hiroki Fukuda, Kazuhiro Shindo, Mari Sakamoto, Tomomi Ide, Shintaro Kinugawa, Arata Fukushima, Akira Ishii, Shin Ito, and Takashi Washio. Hiroyuki Tsutsui reports personal fees from Astellas, personal fees from Ohtsuka, personal fees from Takeda, personal fees from Daiichi-Sankyo, personal fees from Tanabe-Mitsubishi, personal fees from Nippon Boehringer Ingelheim, personal fees from Novartis, personal fees from Bayer, personal fees from Bristol Myers Squibb, outside the submitted work. Masafumi Kitakaze reports grants from Japanese government, during the conduct of the study; grants from Japanese government, grants from Japan Heart Foundation, grants from Japan Cardiovascular Research Foundation, grants and personal fees from Asteras, personal fees from Daiichi-sankyo, grants and personal fees from Pfizer, grants and personal fees from Ono, personal fees from Bayer, grants from Novartis, grants and personal fees from Tanabe-mitubishi, personal fees from Kowa, personal fees from MSD, grants from Nihon Kohden, personal fees from Shionogi, personal fees from Astrazeneca, grants and personal fees from Astra Zeneca, personal fees from Taisho-Toyama, personal fees from Toyama-Kagaku, grants and personal fees from Kureha, personal fees from Toaeiyo, outside the submitted work.
Funding Information:
This research was funded by Grants-in-Aid from the Ministry of Health, Labour and Welfare of Japan ; Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan ; and Grants-in-Aid from the Japan Agency for Medical Research and Development ( JP17ek0210080 ). These funding sources did not play any role in the study design, data colletion, data anaylsis, interpretation, writing of reports or decision to submit the paper for the publication in the present study.
Publisher Copyright:
© 2018 The Authors
PY - 2018/7
Y1 - 2018/7
N2 - Background: In previous retrospective studies, we identified the 50 most influential clinical predictors of cardiovascular outcomes in patients with heart failure (HF). The present study aimed to use the novel limitless-arity multiple-testing procedure to filter these 50 clinical factors and thus yield combinations of no more than four factors that could potentially predict the onset of cardiovascular events. A Kaplan–Meier analysis was used to investigate the importance of the combinations. Methods: In a multi-centre observational trial, we prospectively enrolled 213 patients with HF who were hospitalized because of exacerbation, discharged according to HF treatment guidelines and observed to monitor cardiovascular events. After the observation period, we stratified patients according to whether they experienced cardiovascular events (rehospitalisation or cardiovascular death). Findings: Among 77,562 combinations of fewer than five clinical parameters, we identified 151 combinations that could potentially explain the occurrence of cardiovascular events. Of these, 145 combinations included the use of inotropic agents, whereas the remaining 6 included the use of diuretics without bradycardia or tachycardia, suggesting that the high probability of cardiovascular events is exclusively determined by these two clinical factors. Importantly, Kaplan–Meier curves demonstrated that the use of inotropes or of diuretics without bradycardia or tachycardia were independent predictors of a markedly worse cardiovascular prognosis. Interpretation: Patients treated with either inotropic agents or diuretics without bradycardia or tachycardia were at a higher risk of cardiovascular events. The uses of these drugs, regardless of heart rate, are the strongest clinical predictors of cardiovascular events in patients with HF.
AB - Background: In previous retrospective studies, we identified the 50 most influential clinical predictors of cardiovascular outcomes in patients with heart failure (HF). The present study aimed to use the novel limitless-arity multiple-testing procedure to filter these 50 clinical factors and thus yield combinations of no more than four factors that could potentially predict the onset of cardiovascular events. A Kaplan–Meier analysis was used to investigate the importance of the combinations. Methods: In a multi-centre observational trial, we prospectively enrolled 213 patients with HF who were hospitalized because of exacerbation, discharged according to HF treatment guidelines and observed to monitor cardiovascular events. After the observation period, we stratified patients according to whether they experienced cardiovascular events (rehospitalisation or cardiovascular death). Findings: Among 77,562 combinations of fewer than five clinical parameters, we identified 151 combinations that could potentially explain the occurrence of cardiovascular events. Of these, 145 combinations included the use of inotropic agents, whereas the remaining 6 included the use of diuretics without bradycardia or tachycardia, suggesting that the high probability of cardiovascular events is exclusively determined by these two clinical factors. Importantly, Kaplan–Meier curves demonstrated that the use of inotropes or of diuretics without bradycardia or tachycardia were independent predictors of a markedly worse cardiovascular prognosis. Interpretation: Patients treated with either inotropic agents or diuretics without bradycardia or tachycardia were at a higher risk of cardiovascular events. The uses of these drugs, regardless of heart rate, are the strongest clinical predictors of cardiovascular events in patients with HF.
UR - http://www.scopus.com/inward/record.url?scp=85048930452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048930452&partnerID=8YFLogxK
U2 - 10.1016/j.ebiom.2018.06.001
DO - 10.1016/j.ebiom.2018.06.001
M3 - Article
C2 - 29936136
AN - SCOPUS:85048930452
SN - 2352-3964
VL - 33
SP - 185
EP - 195
JO - EBioMedicine
JF - EBioMedicine
ER -